Bausch + Lomb(NYSE) BLCO

Bausch + Lomb Corporation makes items that help people see. They sell contact lenses and surgical tools to patients. These items fix blurry vision and treat common eye diseases.

From Lenses to Lasers

• Vision Care: Contact lenses and non-prescription items like vitamins and lens care products; accounted for 56% of total revenues in the three months ended June 30, 2026.
• Pharmaceuticals: Prescription drugs for glaucoma, dry eye, and inflammation; made up 26% of total revenues in the three months ended June 30, 2026.
• Surgical: Tools, implants, and lasers used for cataract and retinal surgeries; represented 18% of total revenues in the three months ended June 30, 2026.

New Tools and Fresh Starts

• Acquired Elios Vision, Inc. in Dec. 2024 to add laser procedures for glaucoma treatment to its portfolio.
• Launched Blink NutriTears in June 2024, a supplement designed to target the root causes of dry eyes.
• Introduced a preservative-free version of Lumify eye drops in the first quarter of 2025.
• Acquired Whitecap Biosciences in 2025 to supplement research and development for future eye care products.
• Began launching Blink Nourish and Blink Boost lubricating eye drops in the U.S. during June 2025.

A Broad Global Eye Network

The company operates a fully integrated business with a portfolio of approximately 400 products marketed in about 100 countries. A dedicated team of 900 research and development employees focuses on clinical trials to meet international regulatory standards.

Checking the Financial Pulse

• Total revenues were $1.39 billion in the three months ended June 30, 2026, up 9% year over year.
• Operating income reached $83 million in the three months ended June 30, 2026.
• Net loss was $14 million in the three months ended June 30, 2026.
• Net cash provided by operating activities was $185 million for the six months ended June 30, 2026.

A Final Look Ahead

Bausch + Lomb has transitioned into an independent eye health company by expanding its surgical and pharmaceutical portfolios. Its focus on integrated eye care and product innovation helps address unmet needs in global vision health.